EXOZYMES INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | $70.1K |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $3.7M | $1.9M | $527.5K |
| SG&A Expense | — | $6.0M | $4.1M | $1.3M |
| Operating Income | — | $-9.7M | $-5.9M | $-1.8M |
| Operating Margin | — | — | — | -2,563.5% |
| Interest Expense | — | — | — | — |
| Pretax Income | — | $-9.3M | $-5.9M | $-2.0M |
| Income Tax Expense | — | $-105.2K | — | $42.3K |
| Net Income | — | $-9.2M | $-5.9M | $-2.0M |
| Net Margin | — | — | — | -2,909.1% |
| EPS (Basic) | — | $-1.09 | $-0.89 | $-0.33 |
| EPS (Diluted) | — | $-1.09 | $-0.89 | $-0.33 |
| Shares Outstanding (Basic) | 8.5M | 8.4M | 6.6M | 6.3M |
| Shares Outstanding (Diluted) | 8.5M | 8.4M | 6.6M | 6.3M |
| Dividends Per Share | — | — | — | — |